Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
Mrinalini Dey DrMiniDey
1 week 2 days ago
Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084
ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
💊 Oral IL-23Ri for #PsA #PsO?
ICONIC RCT (n=216):
Yes! Icotrokinra improves pain & disease activity at week 16
#POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🛡️ Can secukinumab prevent #PsA?
SERENA real-world study (n=1,334):
Yes!
97% PsA-free at 5yrs
#POS0051 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
💉 Add tirzepatide to biologics in obese #PsA?
#POS0050: Yes! Propensity score-matched study (n=93):
better PROs, HAQ & PASI at 6 months
#EULAR2026 @RheumNow
@vincevenerito https://t.co/rrhNKZByjc
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🎯 Does Tofacitinib work in axial #PsA?
#POS0049: 1st RCT (PASTOR, n=26):
improved MRI & clinical outcomes vs placebo @ wk12
#EULAR2026 @rheumnow
Janet Pope Janetbirdope
1 week 2 days ago
You CAN identify #ILD in #rheumatic #diseases
🔜early
With a brief #questionnaire
Ask re
➡️dry cough
➡️dyspnea
➡️smoking
Not sensitive but high #specificity
Is it too late?
Maybe chest #auscultation at the #bases would be better?
🤷
#EULAR2026 ABST#POS0433
@RheumNow https://t.co/JA3k1cSHt7
Jiha Lee JihaRheum
1 week 2 days ago
Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
BKZ protect joints in #PsA long-term?
#POS0048: Phase 3 RCT+OLE (n=579):
74% no x-ray progression at 3 yrs,
across all subgroups 💪
#EULAR2026 @RheumNow https://t.co/BftcHDKS4l
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
💉 Risankizumab durable in #PsA?
#POS0047 3 RCT n=964 KEEPsAKE
Yes! ACR50 ~37% & MDA ~34% @w244
no new safety signals 💪
#EULAR2026 @RheumNow https://t.co/911Fi9vxfP
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🤔 Best endpoint for #PsA trials?
#POS0046: GRAPPA-OMERACT NMA (24 trials, n=12,000):
MDA wins! (OR 5.06) 📊
#EULAR2026 @RheumNow https://t.co/3KWaKcvF0a
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🤔 GUS or IL-17i for #PsA?
#POS0045: RW study:
Both! ~76% persistence & similar effectiveness
1141 pts @12mo #PsABIOnd 🌍
#EULAR2026 @RheumNow https://t.co/PyuaH5B5V1
Jiha Lee JihaRheum
1 week 2 days ago
In #PsA, obesity isn't just a comorbidity, it's a disease modifier. Pooled SPIRIT trials (n=1284): 43% had obesity. BMI≥30 vs normal: joint counts ↑, function ↓, fatigue ↑, CVD 55% vs 18%, HTN 52% vs 11%, DM 19% vs 3%. @RheumNow #EULAR2026 POS0460
Janet Pope Janetbirdope
1 week 2 days ago
Does #Rx w #immunesuppression w
#antifibrotic
Help #SARD-ILD?
YES.
N=40 SARD-ILD, 1/2 w UIP pattern
Use of #IS w #antifibrotic pt group had better survival
Small N and ?channeling bias
But interesting results
TAke home : Use IS + antifibrotic
#EULAR2026 #POS0530
@RheumNow https://t.co/tfxVVw27jJ
Jiha Lee JihaRheum
1 week 2 days ago
Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of sex, BMI, MTX use, or joint counts. Highest inflammation and erosion burden? Biggest benefit. IL-23i holds up where it matters most. @RheumNow #EULAR2026 POS0480
